Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1997-1-6
|
pubmed:abstractText |
Seroconversion after hepatitis B vaccine has been estimated to occur when the level of anti-HBs is higher than 10 IU/1, but recently is has been considered that an antibody titer above 100 IU/1 is necessary to guarantee an efficacious protection. We prospectively studied the evolution of anti-HBs after primary vaccination (3 doses; Engerix B, 40 mu g each) in 56 seronegative and not previously vaccinated hemodialysis patients. Three months after vaccine administration, seroconversion (anti-HBs > 10 IU/1) was found in 43 patients (76.7%), but an adequate response (titer > 100 IU/1) was observed only in 30 (53.5%). At 1 year after vaccination only 1 (3.3%) of the 30 cases with an effective response had lost his anti-HBs, while 12 of the 13 patients (92.3%) with an inadequate response (anti-HBs between 10 and 100 IU/1) had no detectable antibodies (p < 0.01, chi2). Considering that an antibody titer above 100 IU/1 following vaccination is necessary in order to maintain that level of antibody 1 year later, we analyzed the factors which influenced obtaining this level of antibody. Age, time on hemodialysis, serum albumin, Kt/V and protein catabolic rate did not affect the response to the vaccine. Females had a better response than males, and interestingly we found that hepatitis C virus (HCV) infection influenced the level of immunity. 27 out of the 43 HCV-negative cases (62.7%) obtained anti-HBs levels greater than 100 IU/1, but only 3 out of the 13 HCV-infected patients (23%) had an anti-HBs above 100 IU/1 (p < 0.01, chi2). Our results suggest that after hepatitis B vaccine, an antibody titer higher than 100 IU/1 is necessary to maintain the antibody level 1 year later, and that HCV infection may reduce the effectiveness of hepatitis B vaccine in hemodialysis patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0250-8095
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
95-7
|
pubmed:dateRevised |
2007-2-14
|
pubmed:meshHeading |
pubmed-meshheading:8919223-Adolescent,
pubmed-meshheading:8919223-Adult,
pubmed-meshheading:8919223-Aged,
pubmed-meshheading:8919223-Female,
pubmed-meshheading:8919223-Hepatitis B,
pubmed-meshheading:8919223-Hepatitis B Antibodies,
pubmed-meshheading:8919223-Hepatitis B Vaccines,
pubmed-meshheading:8919223-Hepatitis C,
pubmed-meshheading:8919223-Hepatitis C Antibodies,
pubmed-meshheading:8919223-Humans,
pubmed-meshheading:8919223-Kidney Failure, Chronic,
pubmed-meshheading:8919223-Male,
pubmed-meshheading:8919223-Middle Aged,
pubmed-meshheading:8919223-Prospective Studies,
pubmed-meshheading:8919223-Renal Dialysis,
pubmed-meshheading:8919223-Vaccination
|
pubmed:year |
1996
|
pubmed:articleTitle |
Antibody level after hepatitis B vaccination in hemodialysis patients: influence of hepatitis C virus infection.
|
pubmed:affiliation |
Department of Nephrology, Hospital Ramon y Cajal, Madrid, Spain.
|
pubmed:publicationType |
Journal Article
|